drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous bispecific CAR-T cell therapy engineered to target BCMA and CS1 (SLAMF7) on myeloma cells; CAR engagement activates T cells (CD3ΞΆ with co-stimulatory signaling) leading to cytokine release and tumor cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous bispecific CAR-T cells engineered (e.g., via lentiviral transduction) to recognize BCMA and CS1/SLAMF7 on myeloma cells. Antigen binding activates CD3zeta and co-stimulatory signaling domains, driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA/CS1-positive tumor cells, with dual targeting intended to reduce antigen escape.
drug_name
CART-BCMA/CS1
nct_id_drug_ref
NCT05950113